Clutching on straws here, that is statistically non comparable between a population and a sample but an analogy follows
'The study’s Principal Investigator, Professor Joseph Sparano, MD of Montefiore Cancer Center, said “Only about 15% of patients with ER+, HER2-negative breast cancer achieve a pathologic response to neoadjuvant chemotherapy – we are therefore very encouraged to see that one of the two patients with ER+ disease treated thus far have had a pathologic response. This provides an encouraging signal as we initiate the Phase 2 trial.” '
We could easily state that patients with the ER+ disease of this study had over 300 percent success compared to the baseline
Of course, 2 patient comparison to baseline is insignificant for power
Yet, the recipient of this drug also has significance
Looking forward to the quarter, hopefully a fuller data set presents
Luck to holders.
PTX Price at posting:
9.9¢ Sentiment: Hold Disclosure: Held
